+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Branded Generics Market by Product, Drug Type, Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Branded Generics Market by Product, Drug Type, Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Branded Generics Market by Product, Drug Type, Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5896414
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Branded Generics Market grew from USD 432.30 billion in 2023 to USD 494.29 billion in 2024. It is expected to continue growing at a CAGR of 14.66%, reaching USD 1.12 trillion by 2030.

The branded generics market encompasses those pharmaceuticals that are bioequivalent to generic drugs but marketed under a proprietary brand name. These products bridge the gap between patented drugs and conventional generics, offering affordability while ensuring brand adherence. The necessity of branded generics is primarily driven by the need for cost-effective healthcare solutions without compromising quality, particularly in regions with price-sensitive consumers and robust regulatory frameworks. Applications predominantly lie in the treatment of chronic and acute diseases, catering to both outpatient and long-term healthcare facilities. End-use sectors include hospitals, clinics, and home healthcare, all seeking to leverage the credibility associated with established brands at reduced costs.

Key growth factors promoting the expansion of the branded generics market include the increasing prevalence of chronic diseases, rising healthcare costs, and the expiry of blockbuster drug patents which paves the way for branded generic replacements. Moreover, burgeoning demand in emerging markets, where healthcare infrastructure is rapidly developing, offers significant expansion opportunities. To capitalize on these opportunities, companies should focus on strategic partnerships and localization strategies to enhance regional presence and align with consumer needs. However, challenges such as stringent regulatory requirements and intense competition from local and multinational generics manufacturers pose potential hindrances. Additionally, misconceptions regarding the efficacy of generics and branded generics can limit market acceptance.

In terms of innovation, the incorporation of advanced drug delivery systems and the development of differentiated and specialty branded generics present lucrative research avenues, potentially enhancing market share and customer loyalty. The market is dynamic, influenced greatly by healthcare policies, reimbursement scenarios, and consumer perceptions. For businesses looking to thrive, continuous market research and adaptive strategies, including diversification of product portfolios and investment in consumer education, are essential to overcoming barriers and capturing sustained market growth.

Understanding Market Dynamics in the Branded Generics Market

The Branded Generics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of chronic diseases necessitating the use of generic medications
    • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • Market Restraints
    • Concerns associated with quality variations in branded generic medications
  • Market Opportunities
    • Novel bioequivalence studies and efforts by market players to expand branded generics business
  • Market Challenges
    • Litigation issues and issues related to price erosion of innovator drugs

Exploring Porter’s Five Forces for the Branded Generics Market

Porter’s Five Forces framework further strengthens the insights of the Branded Generics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Branded Generics Market

External macro-environmental factors deeply influence the performance of the Branded Generics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Branded Generics Market

The Branded Generics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Branded Generics Market

The Branded Generics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy’s Laboratories Ltd., Lupin Limited, Viatris Inc., Sandoz International GmbH by Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, Amneal Pharmaceuticals LLC, Eris Lifesciences Limited, Alkem Laboratories Ltd., Cipla Limited, Zentiva Group, a.s., Nichi-Iko Pharmaceutical Co., Ltd., Endo International PLC, Aurobindo Pharma Limited, AstraZeneca PLC, Eva Pharma, Hetero Drugs Limited, Abbott Laboratories, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Pfizer Inc., Aspen Pharmacare Holdings Limited, Sun Pharmaceutical Industries Ltd., Ajanta Pharma Ltd., Apotex Inc., Bristol-Myers Squibb Company, Sanofi S.A., Micro Labs Limited, Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Trade Named Generics
    • Value-Added
  • Drug Type
    • Alkylating Agents
    • Anti-depressants
    • Anti-epileptics
    • Anti-hypertensive
    • Anti-psychotics
    • Antimetabolites
    • Hormones
    • Lipid Lowering Drugs
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Indication
    • Acute & Chronic Pain
    • Cardiovascular Diseases
    • Dermatological Diseases
    • Gastrointestinal Diseases
    • Neurological Diseases
    • Oncology
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
5.1.2. Restraints
5.1.2.1. Concerns associated with quality variations in branded generic medications
5.1.3. Opportunities
5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
5.1.4. Challenges
5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
5.2. Market Segmentation Analysis
5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Branded Generics Market, by Product
6.1. Introduction
6.2. Trade Named Generics
6.3. Value-Added
7. Branded Generics Market, by Drug Type
7.1. Introduction
7.2. Alkylating Agents
7.3. Anti-depressants
7.4. Anti-epileptics
7.5. Anti-hypertensive
7.6. Anti-psychotics
7.7. Antimetabolites
7.8. Hormones
7.9. Lipid Lowering Drugs
8. Branded Generics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
8.4. Topical
9. Branded Generics Market, by Indication
9.1. Introduction
9.2. Acute & Chronic Pain
9.3. Cardiovascular Diseases
9.4. Dermatological Diseases
9.5. Gastrointestinal Diseases
9.6. Neurological Diseases
9.7. Oncology
10. Branded Generics Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.2.1. Hospital Pharmacy
10.2.2. Retail Pharmacy
10.3. Online
11. Americas Branded Generics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Branded Generics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Branded Generics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Vyvanse Generics Approved by FDA
14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
14.3.5. Dr Reddy’s Enters Trade Generics Business In Domestic Market
14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
14.3.8. Cipla Launches ‘Easylax L’,A Sugar-Free Oral Emulsion Laxative For Constipation Relief
14.3.9. Procaps Group to Acquire Grupo Somar from Advent International
List of Figures
FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRANDED GENERICS MARKET DYNAMICS
TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 55. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 56. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 87. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 88. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 93. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. FRANCE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. GERMANY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. GERMANY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 196. ITALY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. ITALY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. ITALY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. NORWAY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. NORWAY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 220. POLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 221. POLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. POLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. POLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 226. QATAR BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. QATAR BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. QATAR BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. SPAIN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 254. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. SPAIN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. TURKEY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. TURKEY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. TURKEY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 286. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 287. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Branded Generics market, which are profiled in this report, include:
  • Dr. Reddy’s Laboratories Ltd.
  • Lupin Limited
  • Viatris Inc.
  • Sandoz International GmbH by Novartis AG
  • Bausch Health Companies Inc.
  • GlaxoSmithKline PLC
  • Amneal Pharmaceuticals LLC
  • Eris Lifesciences Limited
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Zentiva Group, a.s.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Endo International PLC
  • Aurobindo Pharma Limited
  • AstraZeneca PLC
  • Eva Pharma
  • Hetero Drugs Limited
  • Abbott Laboratories
  • Glenmark Pharmaceuticals Limited
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Aspen Pharmacare Holdings Limited
  • Sun Pharmaceutical Industries Ltd.
  • Ajanta Pharma Ltd.
  • Apotex Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Micro Labs Limited
  • Torrent Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 494.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 1120 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Branded Generics Global Market Report 2024 - Product Image

Branded Generics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Branded Generics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Branded Generics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 97 Pages
  • Global
From
2024 Global Forecast for Branded Generics (2025-2030 Outlook) - High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Branded Generics (2025-2030 Outlook) - High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2024-2032 - Product Image

Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2024-2032

  • Report
  • 134 Pages
  • Global
From
Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032 - Product Image

Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032

  • Report
  • 121 Pages
  • Canada
From

About the Branded Generics Market

Branded generics are generic drugs that are marketed under a brand name. They are typically manufactured by a generic drug company, but are sold under a brand name owned by a pharmaceutical company. Branded generics are typically sold at a higher price than generic drugs, but are still much cheaper than the original brand-name drug. They are often used to increase the market share of a generic drug company, as well as to increase the visibility of a generic drug in the marketplace. Branded generics are becoming increasingly popular in the pharmaceutical industry, as they offer a cost-effective alternative to brand-name drugs. They are also used to increase the market share of generic drug companies, as well as to increase the visibility of generic drugs in the marketplace. Some companies in the branded generics market include Teva Pharmaceuticals, Mylan, Sandoz, and Dr. Reddy's Laboratories. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.